ticlopidine and Pulmonary Disease, Chronic Obstructive studies

Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.

Pulmonary Disease, Chronic Obstructive: A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.

Research Excerpts

Excerpt	Relevance	Reference
" In the Platelet Inhibition and Patient Outcomes (PLATO) trial, ticagrelor versus clopidogrel reduced the primary endpoint of death from vascular causes, myocardial infarction, or stroke after ACS, but increased the incidence of dyspnea, which may lead clinicians to withhold ticagrelor from COPD patients."	9.20	Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial. ( Andell, P; Cannon, CP; Cyr, DD; Erlinge, D; Himmelmann, A; Husted, S; James, SK; Keltai, M; Koul, S; Santoso, A; Steg, PG; Storey, RF; Wallentin, L, 2015)
" In the Platelet Inhibition and Patient Outcomes (PLATO) trial, ticagrelor versus clopidogrel reduced the primary endpoint of death from vascular causes, myocardial infarction, or stroke after ACS, but increased the incidence of dyspnea, which may lead clinicians to withhold ticagrelor from COPD patients."	5.20	Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial. ( Andell, P; Cannon, CP; Cyr, DD; Erlinge, D; Himmelmann, A; Husted, S; James, SK; Keltai, M; Koul, S; Santoso, A; Steg, PG; Storey, RF; Wallentin, L, 2015)
"Ticagrelor is a reversible inhibitor of platelet-aggregation, and is used instead of clopidogrel in the treatment of acute coronary syndrome (ACS)."	3.79	[Gastrointestinal bleeding after treatment with ticagrelor]. ( Hauge, J; Kragh, R; Poulsen, BK, 2013)
"Thrombocytosis was associated with both 1-year mortality and inhospital mortality; OR 1."	1.40	Thrombocytosis is associated with increased short and long term mortality after exacerbation of chronic obstructive pulmonary disease: a role for antiplatelet therapy? ( Chalmers, JD; Harrison, MT; Schembri, S; Short, P; Singanayagam, A; Williamson, PA, 2014)
"Chronic obstructive pulmonary disease (COPD) is associated with unfavourable short- and long-term outcome in patients with coronary artery disease undergoing revascularisation procedures."	1.36	Relationship between chronic obstructive pulmonary disease and in-hospital management and outcomes in patients with acute myocardial infarction. ( Brzeziński, M; Dubiel, JS; Dudek, D; Dziewierz, A; Mielecki, W; Rakowski, T; Siudak, Z; Zdzienicka, J, 2010)

Research

Studies (8)

Authors

Clinical Trials (4)

Trial Overview

Trial Outcomes

Participants With Any Event From the Composite of All-cause Mortality, MI, and Stroke

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	8 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Campo, G	1
Vieceli Dalla Sega, F	1
Pavasini, R	1
Aquila, G	1
Gallo, F	1
Fortini, F	1
Tonet, E	1
Cimaglia, P	1
Del Franco, A	1
Pestelli, G	1
Pecoraro, A	1
Contoli, M	1
Balla, C	1
Biscaglia, S	1
Rizzo, P	1
Ferrari, R	1
Hauge, J	1
Kragh, R	1
Poulsen, BK	1
Harrison, MT	1
Short, P	1
Williamson, PA	1
Singanayagam, A	1
Chalmers, JD	1
Schembri, S	1
Sin, DD	1
Jagpal, S	1
Pistun, O	1
Mikhail, J	1
Andell, P	1
James, SK	1
Cannon, CP	1
Cyr, DD	1
Himmelmann, A	1
Husted, S	1
Keltai, M	1
Koul, S	1
Santoso, A	1
Steg, PG	1
Storey, RF	1
Wallentin, L	1
Erlinge, D	1
Grohé, C	1
Dziewierz, A	1
Siudak, Z	1
Rakowski, T	1
Brzeziński, M	1
Zdzienicka, J	1
Mielecki, W	1
Dubiel, JS	1
Dudek, D	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Comparison Between Ticagrelor and Clopidogrel Effect on Endothelial, Platelet and Inflammation Parameters in Patients With Stable Coronary Artery Disease and Chronic Obstructive Pulmonary Disease Undergoing PCI[NCT02519608]	Phase 2	44 participants (Actual)	Interventional	2015-09-30	Completed
Multimodality Investigation of Intermediate Culprit Lesion With Negative Fractional Flow Reserve in Patients With no ST-segment Elevation Acute Coronary Syndrome.[NCT03205514]		35 participants (Actual)	Observational [Patient Registry]	2017-06-28	Completed
REACTIC-TAVI Trial: Platelet REACtivity According to TICagrelor Dose After Transcatheter AorticValve Implantation. A Pilot Study.[NCT04331145]	Phase 4	40 participants (Actual)	Interventional	2020-06-23	Completed
A Randomised, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of Ticagrelor Compared With Clopidogrel for Prevention of Vascular Events in Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS) [PLATO- a Study of PLATelet Inh[NCT00391872]	Phase 3	18,624 participants (Actual)	Interventional	2006-10-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Participants with death from any cause, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal of consent or date of scheduled withdrawal from therapy. ITT analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months

Participants With Any Event From the Composite of Death From Vascular Causes, MI (Including Silent), Stroke, Recurrent Ischemia, Transient Ischemic Attack (TIA) and Other Arterial Thrombotic Events.

Intervention	Participants (Number)
TICAGRELOR	901
CLOPIDOGREL	1065

Participants with death from vascular causes, MI, stroke, recurrent ischemia, or other thrombotic events. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT analysis of whole population. Events were adjudicated. (NCT00391872)
Timeframe: Randomization up to 12 months

Participants With Any Event From the Composite of Death From Vascular Causes, MI, and Stroke for the Subgroup of Patients With Intent for Invasive Management at Randomization

Intervention	Participants (Number)
TICAGRELOR	1290
CLOPIDOGREL	1456

Participants with death from vascular causes, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT analysis of intent for invasive management population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months

Participants With Any Event From the Composite of Death From Vascular Causes, Myocardial Infarction (MI), and Stroke

Intervention	Participants (Number)
TICAGRELOR	569
CLOPIDOGREL	668

Participants with death from vascular causes, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. Intention To Treat (ITT) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months

Participants With Any Major Bleeding Event

Intervention	Participants (Number)
TICAGRELOR	864
CLOPIDOGREL	1014

Participants with major (fatal/life-threatening or other) bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months

Participants With Coronary Artery Bypass Graft (CABG) Major Bleeding

Intervention	Participants (Number)
TICAGRELOR	961
CLOPIDOGREL	929

Participants with a major CABG-related bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. All CABG surgeries were submitted for adjudication by an endpoint committee as potential bleeds. (NCT00391872)
Timeframe: First dosing up to 12 months

Participants With Coronary Artery Bypass Graft (CABG) Major Fatal/Life-threatening Bleeding

Intervention	Participants (Number)
TICAGRELOR	619
CLOPIDOGREL	654

Number of participants with a major fatal/life-threatening CABG-related bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. All CABG surgeries were submitted for adjudication by an endpoint committee as potential bleeds. (NCT00391872)
Timeframe: First dosing up to 12 months

Participants With Death From Any Cause

Intervention	Participants (Number)
TICAGRELOR	329
CLOPIDOGREL	341

Participants with death from any cause. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months

Participants With Death From Vascular Causes

Intervention	Participants (Number)
TICAGRELOR	399
CLOPIDOGREL	506

Participants with death from vascular causes. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months

Participants With Major or Minor Bleeding

Intervention	Participants (Number)
TICAGRELOR	353
CLOPIDOGREL	442

Participants with major (fatal/life-threatening or other) or minor bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months

Participants With MI Event

Intervention	Participants (Number)
TICAGRELOR	1339
CLOPIDOGREL	1215

Participants with MI event. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months

Participants With Non-CABG (Coronary Artery Bypass Graft) Related Major Bleeding

Intervention	Participants (Number)
TICAGRELOR	504
CLOPIDOGREL	593

Participants with non CABG related major (fatal/life-threatening or other) bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months

Participants With Non-procedural Major Bleeding

Intervention	Participants (Number)
TICAGRELOR	362
CLOPIDOGREL	306

Participants with non-procedural major bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months

Participants With Stroke

Intervention	Participants (Number)
TICAGRELOR	235
CLOPIDOGREL	180

Participants with stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months

Participants With Ventricular Pauses of Greater Than or Equal to 3 Seconds in Patients Monitored by Holter 24 Hour ECG Recorders for 1 Week at 1 Month Following Randomization

Intervention	Participants (Number)
TICAGRELOR	125
CLOPIDOGREL	106

Number of participants who were observed to have at least 1 ventricular pause of at least 3 seconds. Population is all patients who were observed over 2 week-long periods. Pauses were flagged algorithmically and confirmed by TIMI cardiologists. (NCT00391872)
Timeframe: 1-week period following randomization

Participants With Ventricular Pauses of Greater Than or Equal to 3 Seconds in Patients Monitored by Holter 24-hour ECG Recorders for 1 Week Following Randomization

Intervention	Participants (Number)
TICAGRELOR	21
CLOPIDOGREL	16

Number of participants who were observed to have at least 1 ventricular pause of at least 3 seconds. Population is all patients who were observed over 2 week-long periods. Pauses were flagged algorithmically and confirmed by Thrombolysis in Myocardial Infarction (TIMI) group cardiologists. (NCT00391872)
Timeframe: 1-week period following randomization

Trials

Other Studies

6 other studies available for ticlopidine and Pulmonary Disease, Chronic Obstructive

Article	Year
Biological effects of ticagrelor over clopidogrel in patients with stable coronary artery disease and chronic obstructive pulmonary disease. Thrombosis and haemostasis, 2017, 03-23, Volume: 117, Issue:6 Topics: Adenosine; Aged; Anticoagulants; Apoptosis; Blood Platelets; Clopidogrel; Coronary Artery Disease; C	2017
Biological effects of ticagrelor over clopidogrel in patients with stable coronary artery disease and chronic obstructive pulmonary disease. Thrombosis and haemostasis, 2017, 03-23, Volume: 117, Issue:6 Topics: Adenosine; Aged; Anticoagulants; Apoptosis; Blood Platelets; Clopidogrel; Coronary Artery Disease; C	2017
Biological effects of ticagrelor over clopidogrel in patients with stable coronary artery disease and chronic obstructive pulmonary disease. Thrombosis and haemostasis, 2017, 03-23, Volume: 117, Issue:6 Topics: Adenosine; Aged; Anticoagulants; Apoptosis; Blood Platelets; Clopidogrel; Coronary Artery Disease; C	2017
Biological effects of ticagrelor over clopidogrel in patients with stable coronary artery disease and chronic obstructive pulmonary disease. Thrombosis and haemostasis, 2017, 03-23, Volume: 117, Issue:6 Topics: Adenosine; Aged; Anticoagulants; Apoptosis; Blood Platelets; Clopidogrel; Coronary Artery Disease; C	2017
Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Journal of the American Heart Association, 2015, Oct-09, Volume: 4, Issue:10 Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Dyspnea; Female; Hemorrhage; Humans; Kaplan-M	2015
Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Journal of the American Heart Association, 2015, Oct-09, Volume: 4, Issue:10 Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Dyspnea; Female; Hemorrhage; Humans; Kaplan-M	2015
Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Journal of the American Heart Association, 2015, Oct-09, Volume: 4, Issue:10 Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Dyspnea; Female; Hemorrhage; Humans; Kaplan-M	2015
Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Journal of the American Heart Association, 2015, Oct-09, Volume: 4, Issue:10 Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Dyspnea; Female; Hemorrhage; Humans; Kaplan-M	2015

Article	Year
[Gastrointestinal bleeding after treatment with ticagrelor]. Ugeskrift for laeger, 2013, Mar-11, Volume: 175, Issue:11 Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Artery Bypass; Female; Gastrointesti	2013
Thrombocytosis is associated with increased short and long term mortality after exacerbation of chronic obstructive pulmonary disease: a role for antiplatelet therapy? Thorax, 2014, Volume: 69, Issue:7 Topics: Aged; Aspirin; Clopidogrel; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Pulm	2014
The devastating power of platelets in COPD exacerbations: can aspirin save lives in COPD? Thorax, 2014, Volume: 69, Issue:7 Topics: Aspirin; Clopidogrel; Female; Humans; Male; Platelet Aggregation Inhibitors; Pulmonary Disease, Chro	2014
Pirfenidone for idiopathic pulmonary fibrosis, thrombocytosis in chronic obstructive pulmonary disease exacerbations, and a longitudinal study on e-cigarettes. American journal of respiratory and critical care medicine, 2014, Sep-15, Volume: 190, Issue:6 Topics: Antifibrinolytic Agents; Aspirin; Drug Delivery Systems; Enzyme Inhibitors; Female; Humans; Idiopath	2014
[Advantages of Ticagrelor outweigh also in COPD patients]. Deutsche medizinische Wochenschrift (1946), 2016, Volume: 141, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Female; Humans; Male; Platelet Aggregation Inhibitors; Pulmonary	2016
Relationship between chronic obstructive pulmonary disease and in-hospital management and outcomes in patients with acute myocardial infarction. Kardiologia polska, 2010, Volume: 68, Issue:3 Topics: Aged; Aspirin; Clopidogrel; Comorbidity; Female; Health Services Accessibility; Hospital Mortality;	2010